Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity - PubMed (original) (raw)
Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity
P S Chen et al. Neuroscience. 2007.
Abstract
Valproic acid (VPA), a widely prescribed drug for seizures and bipolar disorder, has been shown to be an inhibitor of histone deacetylase (HDAC). Our previous study has demonstrated that VPA pretreatment reduces lipopolysaccharide (LPS)-induced dopaminergic (DA) neurotoxicity through the inhibition of microglia over-activation. The aim of this study was to determine the mechanism underlying VPA-induced attenuation of microglia over-activation using rodent primary neuron/glia or enriched glia cultures. Other histone deacetylase inhibitors (HDACIs) were compared with VPA for their effects on microglial activity. We found that VPA induced apoptosis of microglia cells in a time- and concentration-dependent manner. VPA-treated microglial cells showed typical apoptotic hallmarks including phosphatidylserine externalization, chromatin condensation and DNA fragmentation. Further studies revealed that trichostatin A (TSA) and sodium butyrate (SB), two structurally dissimilar HDACIs, also induced microglial apoptosis. The apoptosis of microglia was accompanied by the disruption of mitochondrial membrane potential and the enhancement of acetylation levels of the histone H3 protein. Moreover, pretreatment with SB or TSA caused a robust decrease in LPS-induced pro-inflammatory responses and protected DA neurons from damage in mesencephalic neuron-glia cultures. Taken together, our results shed light on a novel mechanism whereby HDACIs induce neuroprotection and underscore the potential utility of HDACIs in preventing inflammation-related neurodegenerative disorders such as Parkinson's disease.
Figures
Fig. 1
VPA treatment triggers apoptosis in primary rat microglial cultures. Enriched rat microglial cells were treated with various concentrations of VPA for 24 h. A: Cell viability was determined by the MTT analysis. The percentages of viable cells from triplicate determinations are shown as mean ± SEM compared with vehicle control, B: Externalization of PS in microglia exposed to various concentrations of VPA for 12 h or 24 h, as determined using PE-conjugated annexin V followed by flow cytometry analysis. The percentages of apoptotic cells from five independent experiments are shown as mean ± SEM. # p< 0.05, * p<0.001 compared with vehicle control.
Fig. 2
VPA induces DNA fragmentation and morphological changes in microglia-enriched culture. A: DNA fragmentation in cells treated with 0.6 or 1.2 mM of VPA for 24 h was analyzed by agarose gel electrophoresis. The left lane (M) represents the molecular weight marker (100 bp). B: Enriched rat microglial cells treated with vehicle or 0.6 mM VPA for 24 h. The cell morphology was observed using light microscope.
Fig. 3
VPA induces DNA damage in microglia-enriched culture: A TUNEL study. The VPA-treated microglia were fixed with 4% paraformaldehyde followed by TUNEL assays (red) and DAPI staining (blue). Merge: merged images of TUNEL assay and DAPI staining. The photographic figures are from a representative experiment. Arrow: TUNEL-positive cells.
Fig. 4
Treatment with HDACIs induces microglial apoptosis. The enriched microglial cells were treated with 50 nM of TSA or 1.2 mM of SB for 24 h. A: The cell viability was determined by the MTT analysis and the percentages of viable cells from triplicate determinations are shown as mean ± SEM. B: The apoptotic cells were identified using PE-conjugated annexin V followed by flow cytometry analysis at 12 h and 24 h after TSA or SB treatment. The dot plots are from a representative experiment at 24 h (upper panel), and the percentages of apoptotic cells are shown as mean ± SEM from three independent experiments (lower panel). # p< 0.05, * p<0.001 compared with vehicle control.
Fig. 5
Treatment with HDACIs causes a decrease in MTP in the microglial cells. The microglial cell cultures were treated with the indicated concentrations of VPA, TSA, or SB for 24 h. The loss of MTP (ΔΨ_m_) was determined by rhodamine 123 staining. The histograms are from a representative experiment (upper panel). A decrease in rhodamine 123 fluorescence (shift to the left) indicates a decrease in MTP. The percentages of cells with ΔΨm (cells to the left of the white line) are shown as means ± SEM from three independent experiments (lower panel). # p< 0.05, * p<0.001 compared with vehicle control.
Fig. 6
HDACIs increase histone H3 acetylation in the microglial cells. The levels of histone H3 acetylation in the microglial cells treated with 1.2 mM VPA, 50 nM TSA, or 1.2 mM SB for 12 h were analyzed by flow cytometry using specific acetyl-histone H3 antibody conjugated with FITC and PI staining for DNA content as described in the Method. The dot plot (upper panel) of DNA content versus FITC fluorescence for each sample was used to calculate the percentage of histone H3-acetylated cells (green cells). The percentages of histone H3-acetylated cells (lower panel) are shown as mean ± SEM from four independent experiments done in triplicate. *p < 0.001, compared with vehicle control.
Fig. 7
HDACIs failed to change the cell cycle in the microglial cells. The microglial cells were treated with 1.2 mM VPA, 50 nM TSA, or 1.2 mM SB for 24 h and stained with PI. DNA content was analyzed by flow cytometry. The percentages of cells in the sub-G1, G1, S, and G2-M phases of the cell cycle from experiments done in duplicate are shown as mean ± SEM. # p<0.05, compared with vehicle control.
Fig. 8
HDACIs attenuate LPS-induced production of microglial pro-inflammatory factors and reduce microglial dopamingeric neurotoxicity. Mesencephalic neuron-glia cultures were pretreated with 1.2 mM SB or 50 nM TSA for 24 h prior to stimulation with 10 ng/ml LPS. A: The release of TNF-α into the supernatant was determined 3 h post-LPS treatment. B: The level of nitrite in the supernatant, an indicator of NO production, was determined 24 h after LPS treatment. Results of four independent experiments done in triplicate are shown as means ± SEM. * p<0.001 compared with cultures treated with LPS alone. C: Seven days after LPS stimulation, the viability of DA neurons was assessed by DA uptake assays. The ratios of DA uptake capacity from cultures treated with LPS to those without LPS in the same treatment groups. The results of four independent experiments in triplicate are shown as means ± SEM. * p<0.001 compared with LPS alone. D: The morphology of tyrosine hydroxylase-immunoractive neurons. The figures shown are from a representative experiment.
Similar articles
- Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia.
Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, Hong JS. Peng GS, et al. Brain Res Mol Brain Res. 2005 Mar 24;134(1):162-9. doi: 10.1016/j.molbrainres.2004.10.021. Epub 2004 Nov 25. Brain Res Mol Brain Res. 2005. PMID: 15790540 - Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons.
Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, Kinyamu H, Lu N, Gao X, Leng Y, Chuang DM, Zhang W, Lu RB, Hong JS. Wu X, et al. Int J Neuropsychopharmacol. 2008 Dec;11(8):1123-34. doi: 10.1017/S1461145708009024. Epub 2008 Jul 9. Int J Neuropsychopharmacol. 2008. PMID: 18611290 Free PMC article. - 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.
Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, Wilson B, Liu B, Zhang W, Kim HC, Hong JS. Zhang W, et al. FASEB J. 2005 Mar;19(3):395-7. doi: 10.1096/fj.04-1586fje. Epub 2004 Dec 13. FASEB J. 2005. PMID: 15596482 - Effect of valproic acid on histone deacetylase expression in oral cancer (Review).
Al-Khafaji ASK, Wang LM, Alabdei HH, Liloglou T. Al-Khafaji ASK, et al. Oncol Lett. 2024 Mar 7;27(5):197. doi: 10.3892/ol.2024.14330. eCollection 2024 May. Oncol Lett. 2024. PMID: 38516679 Free PMC article. Review. - Parkinsonism: A Rare Adverse Effect of Valproic Acid.
Muralidharan A, Rahman J, Banerjee D, Hakim Mohammed AR, Malik BH. Muralidharan A, et al. Cureus. 2020 Jun 23;12(6):e8782. doi: 10.7759/cureus.8782. Cureus. 2020. PMID: 32724733 Free PMC article. Review.
Cited by
- Interaction between α-Synuclein and Bioactive Lipids: Neurodegeneration, Disease Biomarkers and Emerging Therapies.
Sanluca C, Spagnolo P, Mancinelli R, De Bartolo MI, Fava M, Maccarrone M, Carotti S, Gaudio E, Leuti A, Vivacqua G. Sanluca C, et al. Metabolites. 2024 Jun 22;14(7):352. doi: 10.3390/metabo14070352. Metabolites. 2024. PMID: 39057675 Free PMC article. Review. - Sebacic acid, a royal jelly-containing fatty acid, decreases LPS-induced IL-6 mRNA expression in differentiated human THP-1 macrophage-like cells.
Ogawa E, Suzuki N, Kamiya T, Hara H. Ogawa E, et al. J Clin Biochem Nutr. 2024 May;74(3):192-198. doi: 10.3164/jcbn.23-16. Epub 2023 Nov 22. J Clin Biochem Nutr. 2024. PMID: 38799138 Free PMC article. - Gut-Brain Interactions and Their Impact on Astrocytes in the Context of Multiple Sclerosis and Beyond.
Zißler J, Rothhammer V, Linnerbauer M. Zißler J, et al. Cells. 2024 Mar 13;13(6):497. doi: 10.3390/cells13060497. Cells. 2024. PMID: 38534341 Free PMC article. Review. - Sodium butyrate activates the KATP channels to regulate the mechanism of Parkinson's disease microglia model inflammation.
Xu Y, Wen L, Tang Y, Zhao Z, Xu M, Wang T, Chen Z. Xu Y, et al. Immun Inflamm Dis. 2024 Mar;12(3):e1194. doi: 10.1002/iid3.1194. Immun Inflamm Dis. 2024. PMID: 38501544 Free PMC article. - Spinal cord injury-induced gut dysbiosis influences neurological recovery partly through short-chain fatty acids.
Jing Y, Yang D, Bai F, Wang Q, Zhang C, Yan Y, Li Z, Li Y, Chen Z, Li J, Yu Y. Jing Y, et al. NPJ Biofilms Microbiomes. 2023 Dec 14;9(1):99. doi: 10.1038/s41522-023-00466-5. NPJ Biofilms Microbiomes. 2023. PMID: 38092763 Free PMC article.
References
- Allen MH, Hirschfeld RM, Wozniak PJ, Baker JD, Bowden CL. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry. 2006;163:272–275. - PubMed
- Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today. 2005;10:197–204. - PubMed
- Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature reviews. 2007;8:57–69. - PubMed
- Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784. - PubMed
- Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ, Dangond F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005;164:10–21. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials